MAPT and breast cancer: Figure 6G shows the protein panel predicting sensitivity of BC-PDMs to DTX treatment (Mann Whitney U-test, *p = 0.017) with increased expression of e.g. ERα, luminal-cell marker (CK8/18), inactive beta-catenin-pSer552 and microtubule associated protein Tau-pSer202 (Table 2).